Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint ...Middle East

PR Newswire - News
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi,...

Hence then, the article about jacobio pharma announced its kras g12c inhibitor reached the primary endpoint was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News